Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 5:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 83 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: MRD Assessment Clear all
Completed Phase 3 Interventional Results available

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

NCT00103285
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia
Interventions
3-Dimensional Conformal Radiation Therapy, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Thioguanine, Vincristine Sulfate
Radiation · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 9 Years
Enrollment
5,377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2021
U.S. locations
210
States / cities
Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 151 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2021 · Synced Sep 6, 2026, 5:41 PM EDT
Active, not recruiting Early Phase 1 Interventional

CIPHER Study: Pilot Study to Study the Role of ctDNA in Triple Negative and HER2 Positive Early Stage

NCT05333874
View directory record Official record
Conditions
Breast Cancer, Early-Onset
Interventions
Neoadjuvant chemotherapy administered before surgical extraction of a tumor, Observational
Drug · Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
12
States / cities
Elizabeth, New Jersey • Hamilton, New Jersey • Jersey City, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Sep 6, 2026, 5:41 PM EDT
Completed No phase listed Observational

T-cell Minimal Residual Disease (MRD) Evaluation Using Flow Cytometric Analysis

NCT01078337
View directory record Official record
Conditions
Leukemia, Lymphocytic, Acute
Interventions
bone marrow aspiration, peripheral blood sampling
Procedure
Lead sponsor
Stanford University
Other
Eligibility
Up to 18 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 1, 2010 · Synced Sep 6, 2026, 5:41 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL

NCT04521231
View directory record Official record
Conditions
B Cell Precursor Acute Lymphoblastic Leukemia
Interventions
Blinatumomab
Drug
Lead sponsor
Amgen
Industry
Eligibility
12 Years and older
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
13
States / cities
Clovis, California • Duarte, California • Chicago, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Sep 6, 2026, 5:41 PM EDT
Active, not recruiting Phase 1 Interventional

T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia

NCT01860937
View directory record Official record
Conditions
Relapsed B-Cell Acute Lymphoblastic Leukemia
Interventions
leukapheresis or collection of PBMCs, cyclophosphamide based chemotherapy regimens, modified T cells
Procedure · Drug · Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Up to 26 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Sep 6, 2026, 5:41 PM EDT
Completed Phase 1 Interventional Results available

Post-transplant Flotetuzumab for AML

NCT05506956
View directory record Official record
Conditions
Leukemia, Myeloid, Acute
Interventions
Flotetuzumab
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Sep 6, 2026, 5:41 PM EDT
Not yet recruiting Phase 3 Interventional

Determination 2 - Isatuximab, Iberdomide, Bortezomib and Dexamethasone Induction, Followed by Risk- and Response-Adapted Consolidation and Maintenance Therapy, in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma

NCT07624513
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Isatuximab, Iberdomide, Bortezomib (B), Dexamethasone, Melphalan, Linvoseltamab, On Body Delivery System (OBDS)
Drug · Device
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2038
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Sep 6, 2026, 5:41 PM EDT
Terminated No phase listed Observational

Clinical Performance Evaluation of the C2i-Test

NCT05221827
View directory record Official record
Conditions
Muscle-Invasive Bladder Carcinoma
Interventions
C2i Test
Diagnostic Test
Lead sponsor
C2i Genomics
Industry
Eligibility
22 Years to 100 Years
Enrollment
3 participants
Timeline
2022
U.S. locations
1
States / cities
Bloomfield, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 26, 2023 · Synced Sep 6, 2026, 5:41 PM EDT
Recruiting Phase 2 Interventional

Subcutaneous Blinatumomab for Treatment of Adult Patients With CD19-Positive Mixed Phenotype Acute Leukemia (MPAL)

NCT07222579
View directory record Official record
Conditions
CD19 Positive, Mixed Phenotype Acute Leukemia (MPAL)
Interventions
Subcutaneous Blinatumomab
Drug
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 6, 2026, 5:41 PM EDT
Completed No phase listed Observational

Minimal Residual Disease in Peripheral T-cell Lymphoma

NCT03297697
View directory record Official record
Conditions
Peripheral T Cell Lymphoma
Interventions
Tumor biopsy, Peripheral blood draw, Lymphotrack TCR clonality assay
Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
3
States / cities
Boston, Massachusetts • St Louis, Missouri • New York, New York
Source: ClinicalTrials.gov public record
Updated May 15, 2024 · Synced Sep 6, 2026, 5:41 PM EDT
Completed No phase listed Observational

Assessment of Minimal Residual Disease (MRD) After Antineoplastic Treatment in Patients With AL Amyloidosis

NCT02716103
View directory record Official record
Conditions
Amyloidosis
Interventions
blood collection, bone marrow collection
Other
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 9, 2021 · Synced Sep 6, 2026, 5:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of TAK-951 in Healthy Adults

NCT05567393
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-951 Placebo, TAK-951
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Sep 6, 2026, 5:41 PM EDT
Not yet recruiting Phase 2 Interventional

MRD-Adapted Low-Dose Radiation Therapy During Frontline Chemoimmunotherapy for Diffuse Large B-Cell Lymphoma

NCT07517705
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma
Interventions
Low-Dose Radiation Therapy (LDRT), Standard Frontline Chemoimmunotherapy
Radiation · Other
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Sep 6, 2026, 5:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase 1 TAK-041 First-in-Human Safety, Tolerability, and Pharmacokinetics Study

NCT02748694
View directory record Official record
Conditions
Healthy Volunteers, Schizophrenia
Interventions
TAK-041, TAK-041 Placebo
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Mar 18, 2021 · Synced Sep 6, 2026, 5:41 PM EDT
Recruiting Phase 3 Interventional

Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

NCT07321652
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia
Interventions
Zanubrutinib, Sonrotoclax, Computed Tomography, Bone Marrow Aspiration, Biospecimen Collection, Survey Administration
Drug · Procedure · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
65 Years and older
Enrollment
466 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2038
U.S. locations
210
States / cities
Birmingham, Alabama • Anaheim, California • Baldwin Park, California + 167 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 6, 2026, 5:41 PM EDT
Withdrawn Phase 2 Interventional

A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation

NCT06297629
View directory record Official record
Conditions
Allogeneic Stem Cell Transplantation
Interventions
ASTX727, Donor Lymphocyte Infusion
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Sep 6, 2026, 5:41 PM EDT
Not yet recruiting Phase 2 Interventional

TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma

NCT07502872
View directory record Official record
Conditions
Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Lymphoma, Lymphoma, B-Cell
Interventions
Tafasitamab, Polatuzumab vedotin, Glofitamab, Obinutuzumab
Drug
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 6, 2026, 5:41 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma

NCT03117751
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Lymphoblastic Lymphoma
Interventions
Prednisone, Vincristine, Daunorubicin, Pegaspargase, Erwinase®, Cyclophosphamide, Cytarabine, Mercaptopurine, Dasatinib, Methotrexate, Blinatumomab, Ruxolitinib, Bortezomib, Dexamethasone, Doxorubicin, Etoposide, Clofarabine, Vorinostat, Idarubicin, Nelarabine, Thioguanine, Asparaginase Erwinia chrysanthemi (recombinant)-rywn, Calaspargase Pegol
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
1 Year to 18 Years
Enrollment
790 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
7
States / cities
Palo Alto, California • San Diego, California • Peoria, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 6, 2026, 5:41 PM EDT
Active, not recruiting Phase 1 Interventional

Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19

NCT01044069
View directory record Official record
Conditions
Leukemia, Acute Lymphoblastic Leukemia
Interventions
gene-modified T cells targeted
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced Sep 6, 2026, 5:41 PM EDT
Active, not recruiting Phase 2 Interventional

Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-based Obinutuzumab

NCT05650723
View directory record Official record
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
Interventions
Zanubrutinib Pill, Venetoclax Pill, Obinutuzumab Injection
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Sep 6, 2026, 5:41 PM EDT
Recruiting Phase 3 Interventional

Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC

NCT04585490
View directory record Official record
Conditions
Non Small Cell Lung Cancer, NSCLC, Stage III, Nsclc
Interventions
Durvalumab, Carboplatin, Pemetrexed, Paclitaxel, Cisplatin, AVENIO ctDNA Surveillance Kit, Tremelimumab
Drug · Device
Lead sponsor
Maximilian Diehn
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Sep 6, 2026, 5:41 PM EDT
Completed No phase listed Observational

A Screening Study Targeting Tumor-specific Antigens

NCT05158621
View directory record Official record
Conditions
Metastatic Colorectal Cancer, Stage II/III Colon Cancer
Interventions
blood collection for research (next generation sequencing [NGS]), blood collection for research (HLA typing), blood collection for research (circulating tumor DNA [ctDNA])
Procedure
Lead sponsor
Gritstone bio, Inc.
Industry
Eligibility
12 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
6
States / cities
Miami, Florida • Tamarac, Florida • East Brunswick, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2022 · Synced Sep 6, 2026, 5:41 PM EDT
Active, not recruiting No phase listed Observational

DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas

NCT02633111
View directory record Official record
Conditions
B-cell Non-Hodgkin Lymphoma, Aggressive
Interventions
collected at pre-treatment tumor biopsy, Peripheral blood tests, PET/CT
Other · Device
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
12
States / cities
Miami, Florida • Rochester, Minnesota • Basking Ridge, New Jersey + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Sep 6, 2026, 5:41 PM EDT
Recruiting Early Phase 1 Interventional

VitD3 Supplementation in Patients With Multiple Myeloma

NCT05846880
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Lenalidomide, Maintenance Vitamin D, No maintenance Vitamin D
Drug
Lead sponsor
Amany Keruakous, MD, MS.
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 7, 2025 · Synced Sep 6, 2026, 5:41 PM EDT